Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

<< Previous

Bullboard Posts

Next >>

Comment by stocksnbonds458on May 31, 2023 10:41am

225 Views

Post# 35472408

RE:RE:RE:RE:RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

Perverse and Subversive? What an absolutely assinine comment to make just because you have trouble reading the data as presented. I agree it can be difficult for us to fully understand, but this data is set up now in "FDA speak" in the format that the FDA wants to see, not in Dreimer format.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading